## Pilaipan Puthavathana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5020277/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Influenza A H5N1 Replication Sites in Humans. Emerging Infectious Diseases, 2005, 11, 1036-1041.	4.3	253
2	Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. Journal of General Virology, 2005, 86, 423-433.	2.9	191
3	Apoptosis and Pathogenesis of Avian Influenza A (H5N1) Virus in Humans. Emerging Infectious Diseases, 2007, 13, 708-712.	4.3	140
4	Kinetics and Longevity of Antibody Response to Influenza A H5N1 Virus Infection in Humans. Vaccine Journal, 2009, 16, 978-981.	3.1	42
5	Serological Response to the 2009 Pandemic Influenza A (H1N1) Virus for Disease Diagnosis and Estimating the Infection Rate in Thai Population. PLoS ONE, 2011, 6, e16164.	2.5	40
6	Positive selection at the receptor-binding site of haemagglutinin H5 in viral sequences derived from human tissues. Journal of General Virology, 2008, 89, 1805-1810.	2.9	39
7	Indigenous sources of 2007-2008 H5N1 avian influenza outbreaks in Thailand. Journal of General Virology, 2009, 90, 216-222.	2.9	30
8	Longitudinal study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and mouth disease patients in Thailand, 2000–2017. International Journal of Infectious Diseases, 2019, 80, 84-91.	3.3	29
9	Erythrocyte Binding Preference of Avian Influenza H5N1 Viruses. Journal of Clinical Microbiology, 2007, 45, 2284-2286.	3.9	27
10	Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 833-842.	9.1	27
11	Lack of transmission among healthcare workers in contact with a case of Middle East respiratory syndrome coronavirus infection in Thailand. Antimicrobial Resistance and Infection Control, 2016, 5, 21.	4.1	25
12	Sialic acid content in human saliva and anti-influenza activity against human and avian influenza viruses. Archives of Virology, 2016, 161, 649-656.	2.1	23
13	Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine, 2017, 35, 7339-7346.	3.8	21
14	Complete genome analysis demonstrates multiple introductions of enterovirus 71 and coxsackievirus A16 recombinant strains into Thailand during the past decade. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	20
15	Patient-Based Transcriptome-Wide Analysis Identify Interferon and Ubiquination Pathways as Potential Predictors of Influenza A Disease Severity. PLoS ONE, 2014, 9, e111640.	2.5	19
16	Seroprevalence of antibodies to enterovirus 71 and coxsackievirus A16 among people of various age groups in a northeast province of Thailand. Virology Journal, 2018, 15, 158.	3.4	19
17	Distribution of viral RNA, sialic acid receptor, and pathology in H5N1 avian influenza patients. Apmis, 2010, 118, 895-902.	2.0	18
18	Exposure to cold impairs interferon-induced antiviral defense. Archives of Virology, 2017, 162, 2231-2237	2.1	15

#	Article	IF	CITATIONS
19	Satellite Tracking on the Flyways of Brown-Headed Gulls and Their Potential Role in the Spread of Highly Pathogenic Avian Influenza H5N1 Virus. PLoS ONE, 2012, 7, e49939.	2.5	14
20	The Effect of Detectable HIV Viral Load among HIV-Infected Children during Antiretroviral Treatment: A Cross-Sectional Study. Children, 2018, 5, 6.	1.5	13
21	The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern. Journal of General Virology, 2016, 97, 1311-1323.	2.9	12
22	Serosurveillance for pandemic influenza A (H1N1) 2009 virus infection in domestic elephants, Thailand. PLoS ONE, 2017, 12, e0186962.	2.5	11
23	Microparticle and anti-influenza activity in human respiratory secretion. PLoS ONE, 2017, 12, e0183717.	2.5	11
24	Induction of Cross-Neutralizing Antibody Against H5N1 Virus After Vaccination with Seasonal Influenza Vaccine in COPD Patients. Viral Immunology, 2010, 23, 329-334.	1.3	9
25	Elevation of Cleaved p18 Bax Levels Associated with the Kinetics of Neuronal Cell Death during Japanese Encephalitis Virus Infection. International Journal of Molecular Sciences, 2019, 20, 5016.	4.1	9
26	Biological Properties of H5 Hemagglutinin Expressed by Vaccinia Virus Vector and its Immunological Reactivity with Human Sera. Viral Immunology, 2013, 26, 49-59.	1.3	8
27	Within-host evolutionary dynamics of seasonal and pandemic human influenza A viruses in young children. ELife, 2021, 10, .	6.0	8
28	Replication and cytokine profiles of different subgenotypes of enterovirus 71 isolated from Thai patients in peripheral blood mononuclear cells. Microbial Pathogenesis, 2019, 132, 215-221.	2.9	7
29	Homosubtypic and heterosubtypic antibodies against highly pathogenic avian influenza H5N1 recombinant proteins in H5N1 survivors and non-H5N1 subjects. Virology, 2014, 454-455, 254-262.	2.4	6
30	T cell mediated immunity against influenza H5N1 nucleoprotein, matrix and hemagglutinin derived epitopes in H5N1 survivors and non-H5N1 subjects. PeerJ, 2021, 9, e11021.	2.0	6
31	Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018–2019. Viruses, 2021, 13, 977.	3.3	6
32	A Novel Pathogenic Mechanism of Highly Pathogenic Avian Influenza H5N1 Viruses Involves Hemagglutinin Mediated Resistance to Serum Innate Inhibitors. PLoS ONE, 2012, 7, e36318.	2.5	6
33	Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response. PLoS ONE, 2016, 11, e0153183.	2.5	6
34	Baseline immunity to diphtheria and immunologic response after booster vaccination with reduced diphtheria and tetanus toxoid vaccine in Thai health care workers. American Journal of Infection Control, 2014, 42, e81-e83.	2.3	5
35	Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid. Journal of Virology, 2016, 90, 4637-4646.	3.4	5
36	Mutations in matrix protein 1 and nucleoprotein caused human-specific defects in nuclear exportation and viral assembly of an avian influenza H7N1 virus. Virus Research, 2017, 238, 49-62.	2.2	5

Pilaipan Puthavathana

#	Article	IF	CITATIONS
37	H5N1 NS genomic segment distinctly governs the influenza virus infectivity and cytokine induction in monocytic cells. Asian Pacific Journal of Allergy and Immunology, 2018, 36, 58-68.	0.4	5
38	Satellite telemetry tracks flyways of Asian Openbill storks in relation to H5N1 avian influenza spread and ecological change. BMC Veterinary Research, 2018, 14, 349.	1.9	4
39	Zika virus isolation, propagation, and quantification using multiple methods. PLoS ONE, 2021, 16, e0255314.	2.5	4
40	Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves. PLoS ONE, 2022, 17, e0263316.	2.5	4
41	Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation. International Journal of STD and AIDS, 2016, 27, 761-768.	1.1	3
42	Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses. Vaccine Journal, 2017, 24, .	3.1	3
43	Complete Genomic Sequences of Highly Pathogenic H5N1 Avian Influenza Viruses Obtained Directly from Human Autopsy Specimens. Microbiology Resource Announcements, 2018, 7, .	0.6	3
44	PR8 virus harbouring H5N1 NS gene contributed for THP-1 cell tropism. VirusDisease, 2018, 29, 548-552.	2.0	3
45	Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand. BMC Infectious Diseases, 2021, 21, 1213.	2.9	3
46	Evidence of Influenza A Virus Infection in Cynomolgus Macaques, Thailand. Veterinary Sciences, 2022, 9, 132.	1.7	3
47	Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins. Archives of Virology, 2016, 161, 2693-2704.	2.1	2
48	Response of Severe EV71-Infected Patients to Hyperimmune Plasma Treatment: A Pilot Study. Pathogens, 2021, 10, 625.	2.8	2
49	Substrate specificity of avian influenza H5N1 neuraminidase. World Journal of Virology, 2014, 3, 30.	2.9	2
50	Titration of individual strains in trivalent live-attenuated influenza vaccine without neutralization. Journal of Virological Methods, 2016, 237, 154-158.	2.1	1
51	Single nucleoprotein residue determines influenza A virus sensitivity to an intertypic suppression mechanism. Virology, 2017, 506, 99-109.	2.4	1
52	A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses. Vaccine, 2020, 38, 852-858.	3.8	1
53	Full Genomic Sequences of H5N1 Highly Pathogenic Avian Influenza Virus in Human Autopsy Specimens Reveal Genetic Variability and Adaptive Changes for Growth in MDCK Cell Cultures. BioMed Research International, 2021, 2021, 1-13.	1.9	1
54	Cross-reactive antibodies against H7N9 and H5N1 avian influenza viruses in Thais population. Asian Pacific Journal of Allergy and Immunology, 2017, 35, 20-26.	0.4	1

#	Article	IF	CITATIONS
55	Antiviral effect in association with anti-apoptosis and anti-autophagy of repurposing formoterol fumarate dihydrate on enterovirus A71-infected neuronal cells. Virus Research, 2022, 311, 198692.	2.2	1
56	Influenza A Virus Infection and Nucleotide Sequencing in HIV-Infected Children: A Case Report and Review of Literature. Global Pediatric Health, 2017, 4, 2333794X1771920.	0.7	0